Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile CD274 over exp
Therapy Pembrolizumab
Indication/Tumor Type gastroesophageal junction adenocarcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 over exp gastroesophageal junction adenocarcinoma predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a combined analysis of three clinical trials, Keytruda (pembrolizumab) treatment resulted in favorable outcome in gastric or gastroesophageal junction cancer patients with CD274 (PD-L1) combined positive score (CPS) of 10 or higher, median overall survival, objective response rate, and duration of response were 8 mo, 17% (8/46), 21 mo in KEYNOTE-059, 10 mo, 25% (13/53), not reached in KEYNOTE-061, 17 mo, 25% (23/92), 19 mo in KEYNOTE-062 (PMID: 33446564; NCT02335411, NCT02370498, NCT02494583). 33446564
PubMed Id Reference Title Details
(33446564) Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Full reference...